Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Dombi

Showing results (81-90 of 100) with videos related to

Pageof 10
Sort By:
Journal for Immunotherapy of Cancer|September 4, 2021
Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancerPeter J DeMaria, Katherine Lee-Wisdom, Renee N Donahue, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2021
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform NeurofibromasBrian D Weiss, Pamela L Wolters, Scott R Plotkin, et al.
Sarcoma|November 16, 2017
SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath TumorsChristine S Higham, Seth M Steinberg, Eva Dombi, et al.
The New England Journal of Medicine|December 29, 2016
Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform NeurofibromasEva Dombi, Andrea Baldwin, Leigh J Marcus, et al.
Communications Biology|October 11, 2018
Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1Sara H Isakson, Anthony E Rizzardi, Alexander W Coutts, et al.
Neuro-Oncology|April 25, 2022
Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidityAndrea M Gross, Brittany Glassberg, Pamela L Wolters, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2023
Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in RhabdomyosarcomaSrivandana Akshintala, R Taylor Sundby, Donna Bernstein, et al.
Cell Reports|February 25, 2016
Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma InitiationJianqiang Wu, Vincent W Keng, Deanna M Patmore, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2026
SARC031: A Phase 2 Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST)AeRang Kim, Karla V Ballman, Pamela L Wolters, et al.
Neuro-Oncology|June 3, 2022
Management of neurofibromatosis type 1-associated plexiform neurofibromasMichael J Fisher, Jaishri O Blakeley, Brian D Weiss, et al.
Pageof 10

Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
Journal for Immunotherapy of Cancer|September 4, 2021
Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancerPeter J DeMaria, Katherine Lee-Wisdom, Renee N Donahue, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2021
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform NeurofibromasBrian D Weiss, Pamela L Wolters, Scott R Plotkin, et al.
Sarcoma|November 16, 2017
SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath TumorsChristine S Higham, Seth M Steinberg, Eva Dombi, et al.
The New England Journal of Medicine|December 29, 2016
Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform NeurofibromasEva Dombi, Andrea Baldwin, Leigh J Marcus, et al.
Communications Biology|October 11, 2018
Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1Sara H Isakson, Anthony E Rizzardi, Alexander W Coutts, et al.
Neuro-Oncology|April 25, 2022
Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidityAndrea M Gross, Brittany Glassberg, Pamela L Wolters, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2023
Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in RhabdomyosarcomaSrivandana Akshintala, R Taylor Sundby, Donna Bernstein, et al.
Cell Reports|February 25, 2016
Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma InitiationJianqiang Wu, Vincent W Keng, Deanna M Patmore, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2026
SARC031: A Phase 2 Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST)AeRang Kim, Karla V Ballman, Pamela L Wolters, et al.
Neuro-Oncology|June 3, 2022
Management of neurofibromatosis type 1-associated plexiform neurofibromasMichael J Fisher, Jaishri O Blakeley, Brian D Weiss, et al.
Pageof 10